IL-17
-
How effective is Hengrui’s vunakizumab, the first NMPA-approved anti-IL-17A monoclonal antibody developed in China?
Vunakizumab is a self-developed product of Hengrui Pharmaceuticals, being the first domestically developed recombinant anti-IL-17A humanized monoclonal antibody approved in China, and also the first innovative drug launched by Hengrui in the field of autoimmune diseases
